Consensus Altimmune, Inc.

Stocks

ALT

US02155H2004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:47:54 2026-10-19 EDT			5-day change	1st Jan Change
2.205 ^USD	+0.23%		-13.87%	-38.92%

09-30	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
09-29	Altimmune, Inc. Announces Appointment of Richard Menziuso as Global Controller and Principal Accounting Officer, Effective September 29, 2026	CI

Evolution of the Average Target: Altimmune, Inc.

Evolution of the Target Price: Altimmune, Inc.

Changes in Analyst Recommendations: Altimmune, Inc.

5c3435f4a7c58a5d1f95323a5754904.HoN7eWJlXYZVEWX0XU-06RhD3ICJhOGrH1an-N7jAEQ.Z9kWAxtUHNwzXinCAh3sh0h3ttL9y4Toem7WsbqbVy9w8RkWJ1wS8SdHJA~9049f6dd3356158f4a6dfb543ac1ceda

Analysts' recommendations: Altimmune, Inc.

06-22	Leerink Partners Initiates Altimmune at Outperform With $10 Price Target	MT
04-24	Goldman Sachs Upgrades Altimmune to Neutral From Sell, Adjusts Price Target to $2.50 From $1	MT
03-19	Truist Initiates Altimmune at Buy With $12 Price Target	MT
03-06	B. Riley Adjusts Price Target on Altimmune to $13 From $18, Maintains Buy Rating	MT
01-28	Barclays Initiates Coverage on Altimmune With Overweight Rating, $20 Price Target	MT
25-08-13	UBS Adjusts Price Target on Altimmune to $24 From $26, Maintains Buy Rating	MT
25-08-13	B. Riley Adjusts Price Target on Altimmune to $18 From $20, Maintains Buy Rating	MT
25-02-28	William Blair Initiates Altimmune at Market Perform	MT
25-01-08	Stifel Initiates Altimmune at Buy With $18 Price Target	MT
24-11-12	UBS Initiates Altimmune at Buy With $26 Price Target	MT
24-04-29	Altimmune Shares Decline After Guggenheim Downgrade	MT
24-04-29	Guggenheim Downgrades Altimmune to Neutral From Buy	MT
24-01-17	B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating	MT
23-11-09	B. Riley Lowers Altimmune's PT to 8 From $15, Says Updated Model Adjusts for Ongoing Obesity+NASH Market Dynamics; Maintains Buy Rating	MT
23-08-14	HC Wainwright Adjusts Price Target on Altimmune to $15 From $50, Maintains Buy Rating	MT
23-08-11	B. Riley Lowers Altimmune's Price Target to $15 From $20, Keeps Buy Rating	MT
23-08-10	B. Riley Lowers Altimmune's Price Target to $20 From $26, Keeps Buy Rating	MT
23-03-22	Goldman Sachs Downgrades Altimmune to Neutral From Buy, Adjusts Price Target to $6 From $20	MT
23-01-20	HC Wainwright Reiterates Altimmune at Buy With $50 Price Target	MT
23-01-18	Evercore ISI Adjusts Altimmune Price Target to $25 From $14, Maintains Outperform Rating	MT
22-12-01	Goldman Sachs Initiates Altimmune at Buy With $20 Price Target	MT
22-11-11	JMP Securities Adjusts Price Target on Altimmune to $26 From $28, Maintains Market Outperform Rating	MT
22-09-28	Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight	CI
22-09-16	Guggenheim Adjusts Altimmune's Price Target to $26 From $31, Reiterates Buy Rating	MT
22-08-31	Jefferies Adjusts Altimmune's Price Target to $35 From $30, Reiterates Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALTIMMUNE, INC.					+677.78%
	WUXI APPTEC CO., LTD.					+32.97%
	LONZA GROUP AG					+14.74%
	ARGENX SE					+38.45%
	IQVIA HOLDINGS INC.					+12.07%
	BEONE MEDICINES AG					+18.26%
	REVOLUTION MEDICINES, INC.					+44.87%
	CELLTRION, INC.					+38.06%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	GENMAB A/S					+8.87%
	Average					+91.09%
	Weighted average by Cap.					+27.50%